News

        Beverly Hills, CA, cancer biopharma company Rich Pharmaceuticals has extended its agreement with Princeton, NJ-based CRO Theradex Systems to manage its clinical sites in the U.S. Through this continued deal, Theradex will lead Rich Pharmas new Phase I/II clinical for the treatment of acute myelocytic leukemia and myelodysplastic syndrome patients in the region. Release

        > China-based biotech Henlius has chosen NY cloud software CRO Medidata to help it bring "operational efficiencies" to its ongoing Phase III cancer drug trial in its native country. Release

        > HealthCarePoint, a Texas-based healthcare and clinical research networking-tech company, has completed global testing of its next-gen BlueCloud business model to help healthcare groups and CROs better manage clinical trials. Release



Excerpt from URL:https://www.fiercebiotech.com/cro/spotlight-chinese-biotech-chooses-ny-cro-for-cancer-trial



  ▲ Last article:   Australia-U.S. team IDs way to curb tuberculosis bacterium growth ---Apr 5, 2016
  ▼ Next article:   Former GSK staffers launch new Canadian CRO ---Mar 31, 2016
                    More ……      

 



News FullText Search